A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation EMERALD-2

Brief Summary

Type:
Liver

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03847428

Study #:
STUDY00144417

Start Date:
Jan 22, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03847428

View Complete Trial Details & Eligibility at ClinicalTrials.gov